Alexander A Fitzpatrick
CIK 1398595 · Chief Legal Officer · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$515.5K
Companies
4
Total Filings
43
Lifetime Open-Market Net
-$1.10M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SPRY | Chief Legal Officer | 90,910 | $5.67 | $515.5K | -$1.17M | 7 | 2026-06-12 |
| Evofem Biosciences, Inc. (EVFM) Delisted | General Counsel and Secretary | 275 | $0.01 | $2 | $51.0K | 25 | 2022-02-23 |
| VERENIUM CORP (VRNM) Delisted | Sr. VP General Counsel | 7,496 | — | — | $14.2K | 5 | 2013-08-02 |
| KINTERA INC (UNCL) Delisted | SVP and General Counsel | 0 | — | — | $0 | 3 | 2008-07-10 |
Recent Filings · Page 2 of 5
43 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-04 | Evofem Biosciences, Inc. (EVFM) Delisted | Disp (D) | −120,000 | $0 | EDGAR |
| 2021-12-20 | Evofem Biosciences, Inc. (EVFM) Delisted | Buy (P) | +25,000 | $9.7K | EDGAR |
| 2021-06-10 | Evofem Biosciences, Inc. (EVFM) Delisted | Buy (P) | +10,000 | $10.2K | EDGAR |
| 2021-05-21 | Evofem Biosciences, Inc. (EVFM) Delisted | Tax (F) | −42,120 | -$36.2K | EDGAR |
| 2021-02-03 | Evofem Biosciences, Inc. (EVFM) Delisted | Grant (A) | +200,000 | $0 | EDGAR |
| 2020-11-18 | Evofem Biosciences, Inc. (EVFM) Delisted | Buy (P) | +9,090 | $20.0K | EDGAR |
| 2020-06-08 | Evofem Biosciences, Inc. (EVFM) Delisted | Tax (F) | −31,590 | -$104.6K | EDGAR |
| 2020-05-26 | Evofem Biosciences, Inc. (EVFM) Delisted | Tax (F) | −39,487 | -$197.0K | EDGAR |
| 2020-05-08 | Evofem Biosciences, Inc. (EVFM) Delisted | Tax (F) | −7,802 | -$40.9K | EDGAR |
| 2020-02-07 | Evofem Biosciences, Inc. (EVFM) Delisted | Grant (A) | +150,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.